Cabaletta Bio Q2 2023: cash $176.3M; IND cleared for CABA-201 in myositis

Cabaletta Bio, Inc.

2023-Q2 EPS reported -$0.81

Cash, equivalents & investments of $176.3M as of June 30, 2023, extending runway into Q4 2025.
Net proceeds of ~$93.8M from May 2023 public offering of 8,337,500 shares at $12.00/share.
R&D expenses $11.8M (Q2 2023) vs $9.5M (Q2 2022); G&A $4.1M vs $3.5M.
FDA cleared second IND for CABA-201 in myositis; Fast Track designation granted for SLE/LN.
Anticipates initial 3-month clinical data for CABA-201 by first half of 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Cabaletta Bio, Inc. reported financial results for second quarter ended June 30, 2023.

Period: second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 10, 2023, Cabaletta Bio, Inc. (the “Company”) announced its financial results for the second quarter ended June 30, 2023.

View on SEC.gov

309 earnings releases filed in the last 30 days. Browse all earnings releases →

Cabaletta Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-208095

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.